Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.42 |
| ▸ | NOS3 | P29474 | 6/20 | 0.42 |
| ▸ | REN | P00797 | 7/20 | 0.42 |
| ▸ | NOS1 | P29475 | 5/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRE | P78334 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22063592 | 0.79 | REN (0.47) | NOS2NOS3RENNOS1GABRP | |
| SCHEMBL24722955 | 0.76 | NOS2 (0.42) | NOS2NOS3RENNOS1GABRP | |
| SCHEMBL21287461 | 0.74 | NOS2 (0.44) | NOS2NOS3RENNOS1BACE1 | |
| SCHEMBL29721960 | 0.74 | NOS2 (0.44) | NOS2NOS3RENNOS1BACE1 | |
| SCHEMBL21287270 | 0.74 | NOS3 (0.41) | NOS2NOS3NOS1BACE1 | |
| SCHEMBL22062839 | 0.72 | REN (0.41) | NOS2NOS3RENNOS1GABRP | |
| SCHEMBL24649102 | 0.71 | NOS3 (0.38) | NOS2NOS3NOS1BACE1 | |
| SCHEMBL26759620 | 0.69 | KMT2A (0.39) | NOS2NOS3GABRPGABRDGABRA1 | |
| SCHEMBL25724674 | 0.69 | REN (0.39) | NOS2NOS3RENNOS1GABRP | |
| SCHEMBL9495416 | 0.69 | DHFR (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS2 3039/4885NOS3 3408/4885REN 1170/4885 |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | OXA1L, CACNA1I, GRIK5 | NOS2 4718/4885NOS3 4712/4885REN 3495/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | NOS2 4392/4885NOS3 4050/4885REN 2555/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS2 3039/4885NOS3 3408/4885REN 1170/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | NOS2 3039/4885NOS3 3408/4885REN 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.